A CROSS-SECTIONAL ANALYSIS OF RECENTLY PUBLISHED SYSTEMATIC LITERATURE REVIEWS ON PHARMACOLOGICAL INTERVENTIONS IN ONCOLOGY
Author(s)
Dreitlein WB1, Fowler R2, Jones CA2, Lula S2, McCracken R3, Smoyer KE4
1Envision Pharma Group, Madison, NJ, USA, 2Envision Pharma Group, London, UK, 3Envision Pharma Group, Southport, CT, USA, 4Envision Pharma Group, Philadelphia, PA, USA
OBJECTIVES: Systematic literature reviews (SLRs) play an important role in evidence-based medicine and are increasingly favored over traditional narrative reviews as a method to objectively summarize vast amounts of outcomes data. Our objective was to evaluate a cross-section of published SLRs in oncology and determine the top journals, main purposes, meta-analysis frequency, and sponsorship. METHODS: Searches were conducted in Embase and MEDLINE for the year 2014 and further restricted to cancer topics. Case reports, editorials, conference abstracts, and letters were excluded. Abstracts were manually reviewed to identify SLRs, published in journals, and reporting oncology drug therapy. RESULTS: A total of 1,510 unique citations were identified; 727 were determined to be SLRs in oncology. 9 SLRs included case reports describing rare cancers or adverse drug reactions. Drug therapy was noted in 391 publications (53.8%); 210 included meta-analysis. Journals publishing the largest number of SLRs were PLoS ONE (n=30), Tumor Biology (n=17), Cancer Treatment Reviews (n=15), World Journal of Gastroenterology (n=10) and Journal of Clinical Oncology (n=9). Impact factors for these journals ranged from 2.369 to 17.879. Most frequent purposes were treatment comparisons (27.9%), efficacy assessments (15.6%), and adverse event investigations (14.6%). Foremost cited products were bevacizumab and sorafenib. Sponsorship was independent (43.4%), not reported (28.7%), industry (6.6%), or inaccessible at time of assessment (21.3%). Many SLRs were from China. CONCLUSIONS: In our analysis, PLoS ONE published the most SLRs. Journals offering open access are attracting a growing number of SLRs and many boast a diverse readership. A significant body of work is emerging from China where, as in the rest of the world, the majority of SLRs appear to be independently sponsored. SLRs are valued by clinical, payer, and regulatory decision-makers, since they provide a convenient synthesis of available evidence to address knowledge gaps and facilitate translation of research into practice.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PHP60
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems, Health Care Research, Prescribing Behavior
Disease
Multiple Diseases